We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial) (HYDRA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04315896
Recruitment Status : Completed
First Posted : March 20, 2020
Last Update Posted : February 1, 2022
Sponsor:
Information provided by (Responsible Party):
National Institute of Respiratory Diseases, Mexico

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Double blinded randomized clinical trial designed to evaluate the security and efficacy of hydroxychloroquine as treatment for COVID-19 severe respiratory disease. The investigators hypothesize that a 400mg per day dose of hydroxychloroquine for 10 days will reduce all-cause hospital mortality in patients with severe respiratory COVID-19 disease.

Condition or disease Intervention/treatment Phase
COVID-19 Severe Acute Respiratory Syndrome Drug: Hydroxychloroquine Drug: Placebo oral tablet Phase 3

Detailed Description:
Since hydroxychloroquine is a low cost and safe anti-malaria drug that has proven effects against COVID-19 in vitro. The investigators aim to study the security and efficacy of this drug in trough a double blinded randomized clinical trial. Recruited patients with severe respiratory disease from COVID-19 will be randomized to an intervention group (400mg per day dose of hydroxychloroquine) and placebo. The investigators' main outcome will be all cause hospital mortality. The investigators hypothesize that a 400mg per day dose of hydroxychloroquine for 10 days will reduce all-cause hospital mortality in patients with severe respiratory COVID-19 disease. Results will be compared in an intention to treat analysis. All clinical, analysis and data team members will be blinded to treatment assignment.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 320 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Double blinded, randomized controlled trial
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Clinical practitioners and data analysts will remain blinded all through the study. Blinding will end in case the attending physician considers the patient should abandon the study or some of the exclusion/elimination criteria apply.
Primary Purpose: Treatment
Official Title: Hydroxychloroquine Treatment for Severe COVID-19 Respiratory Disease: Randomised Clinical Trial (HYDRA Trial)
Actual Study Start Date : April 14, 2020
Actual Primary Completion Date : July 1, 2020
Actual Study Completion Date : August 15, 2020

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: treatment
Hydroxychloroquine tablet 200mg every 12 hours for 10 days.
 Drug: Hydroxychloroquine
hydroxychloroquine 400mg day for 10 days
Placebo Comparator: placebo
identical placebo, one tablet every 12 hours for 10 days
 Drug: Placebo oral tablet
Placebo oral tablet


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. All-cause hospital mortality [ Time Frame: From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days ]
    incidence of all-cause mortality


Secondary Outcome Measures :
  1. Length of hospital stay [ Time Frame: From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days ]
    Days from ER admission to hospital discharge

  2. Need of mechanical ventilation [ Time Frame: From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days ]
    need of invasive or non invasive mechanical ventilation

  3. Ventilator free days [ Time Frame: From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days ]
    28 minus days without invasive ventilation support in patients with invasive mechanical ventilation at randomization

  4. Grade 3-4 adverse reaction [ Time Frame: From date of randomization until the date of hospital discharge or date of death from any cause, whichever came first, assessed up to120 days ]
    Adverse Reactions


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Signed informed consent
  2. negative pregnancy test in women
  3. COVID-19 confirmed by rtPCR in any respiratory sample.

  4. Severe COVID-19 disease defined as any from the following:

    1. Pulse oximetry less than 91% or a 3% drop from base pulse oximetry or need to increase supplementary oxygen in chronic hypoxia
    2. Need for mechanical ventilation (invasive or non invasive )
    3. Sepsis/septic shock.

Exclusion Criteria:

  1. history of anaphylactic shock to hydroxychloroquine.
  2. History of previous administration of chloroquine or hydroxychloroquine (within 1 month)
  3. decision of attending physician by any reason.
  4. History of chronic hepatic disease (Child-Pugh B or C)
  5. History of Chronic renal disease (GFR less than 30)
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04315896


Locations
Layout table for location information
Mexico
Instituto Nacional de Enfermedades Respiratorias, "Ismael Cosío Villegas"
Mexico, City, Mexico, 14080
Sponsors and Collaborators
National Institute of Respiratory Diseases, Mexico
Investigators
Layout table for investigator information
Principal Investigator: Carmen Hernandez-Cárdenas, MD. MSc. National Institute of Respiratory Diseases - México
Study Director: Luis-Felipe Jurado-Camacho, MD National Institute of Respiratory Diseases - México
Study Chair: Ireri Thirion-Romero, MD. MSc National Institute of Respiratory Diseases - México
Study Chair: Sebastian Rodriguez-Llamazares, MD.MPH National Institute of Respiratory Diseases - México
Study Director: Rogelio Perez-Padilla, MD. PhD National Institute of Respiratory Diseases - México
Study Chair: Cristobal Guadarrama, MD MSc National Institute of Respiratory Diseases - México
Study Chair: Joel Vasquez-Pérez, MD National Institute of Respiratory Diseases - México
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: National Institute of Respiratory Diseases, Mexico
ClinicalTrials.gov Identifier: NCT04315896    
Other Study ID Numbers: HidroxycloroquinaCOVID19
First Posted: March 20, 2020    Key Record Dates
Last Update Posted: February 1, 2022
Last Verified: January 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: As requested by other investigators.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by National Institute of Respiratory Diseases, Mexico:
COVID-19
Severe acute respiratory syndrome
Additional relevant MeSH terms:
Layout table for MeSH terms
COVID-19
Severe Acute Respiratory Syndrome
Pneumonia, Viral
Pneumonia
Respiratory Tract Infections
Infections
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
 Lung Diseases
Respiratory Tract Diseases
Hydroxychloroquine
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antirheumatic Agents